MA46479A - Procédés et intermédiaires pour la préparation de nouveaux composés substitués de 6,7-dihydro-5h-benzo[7]annulène - Google Patents

Procédés et intermédiaires pour la préparation de nouveaux composés substitués de 6,7-dihydro-5h-benzo[7]annulène

Info

Publication number: MA46479A
Authority: MA; Morocco
Prior art keywords: annulen; intermediaries; benzo; dihydro; preparation
Prior art date: 2016-02-15

Application number

MA046479A

Other languages

English (en)

Inventor

Monsif Bouaboula

Maurice Brollo

Victor Certal

Youssef El-Ahmad

Bruno Filoche-Romme

Frank Halley

Gary Mccort

Laurent Schio

Michel Tabart

Corinne Terrier

Fabienne Thompson

Original Assignee

Sanofi Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-02-15

Filing date

2017-02-14

Publication date

2019-08-14

2017-02-14 Application filed by Sanofi Sa filed Critical Sanofi Sa

2019-08-14 Publication of MA46479A publication Critical patent/MA46479A/fr

Links

150000001875 compounds Chemical group 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/027—Organoboranes and organoborohydrides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Epidemiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pregnancy & Childbirth (AREA)
Gynecology & Obstetrics (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Diabetes (AREA)
Oncology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Pyrrole Compounds (AREA)
Steroid Compounds (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

MA046479A 2016-02-15 2017-02-14 Procédés et intermédiaires pour la préparation de nouveaux composés substitués de 6,7-dihydro-5h-benzo[7]annulène MA46479A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP16305174		2016-02-15

Publications (1)

Publication Number	Publication Date
MA46479A true MA46479A (fr)	2019-08-14

Family

ID=55398242

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
MA44226A MA44226B1 (fr)	2016-02-15	2017-02-14	Dérivés de 6,7-dihydro-5h-benzo[7]annulène comme modulateurs de récepteurs d' oestrogènes
MA046479A MA46479A (fr)	2016-02-15	2017-02-14	Procédés et intermédiaires pour la préparation de nouveaux composés substitués de 6,7-dihydro-5h-benzo[7]annulène

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
MA44226A MA44226B1 (fr)	2016-02-15	2017-02-14	Dérivés de 6,7-dihydro-5h-benzo[7]annulène comme modulateurs de récepteurs d' oestrogènes

Country Status (37)

Country	Link
US (7)	US9714221B1 (fr)
EP (2)	EP3416962B1 (fr)
JP (4)	JP6425852B1 (fr)
KR (2)	KR102813741B1 (fr)
CN (2)	CN112979524B (fr)
AR (1)	AR107616A1 (fr)
AU (2)	AU2017221083B2 (fr)
BR (1)	BR112018016490A2 (fr)
CA (1)	CA3014424A1 (fr)
CL (1)	CL2018002290A1 (fr)
CO (1)	CO2018009534A2 (fr)
CR (1)	CR20180442A (fr)
CY (1)	CY1125165T1 (fr)
DK (2)	DK3524600T3 (fr)
DO (1)	DOP2018000184A (fr)
EA (2)	EA034994B1 (fr)
EC (1)	ECSP18069466A (fr)
ES (2)	ES2881508T3 (fr)
HR (1)	HRP20211043T1 (fr)
HU (2)	HUE057892T2 (fr)
IL (2)	IL261099B (fr)
LT (1)	LT3416962T (fr)
MA (2)	MA44226B1 (fr)
MX (2)	MX380091B (fr)
MY (2)	MY206566A (fr)
PE (1)	PE20181893A1 (fr)
PH (1)	PH12018501679A1 (fr)
PL (1)	PL3416962T3 (fr)
PT (1)	PT3416962T (fr)
RS (1)	RS62132B1 (fr)
SG (2)	SG11201806829TA (fr)
SI (1)	SI3416962T1 (fr)
TN (1)	TN2018000285A1 (fr)
TW (3)	TWI779621B (fr)
UY (1)	UY37124A (fr)
WO (1)	WO2017140669A1 (fr)
ZA (1)	ZA201805137B (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SG11201806829TA (en) *	2016-02-15	2018-09-27	Sanofi Sa	6,7-dihydro-5h-benzo[7]annulene derivatives as estrogen receptor modulators
EP3541809B1 (fr) *	2016-11-17	2025-06-25	Sanofi	Composés n-(3-fluoropropyl)-pyrrolidine substitués, leurs procédés de préparation et leurs utilisations thérapeutiques
KR20190117582A (ko)	2017-02-10	2019-10-16	쥐원 쎄라퓨틱스, 인크.	벤조티오펜 에스트로겐 수용체 조정제
EP3434272A1 (fr)	2017-07-25	2019-01-30	Sanofi	Combinaison comprenant du palbociclib et 6-(2,4-dichlorophényl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulène-2-acide carboxylique
KR102765922B1 (ko) *	2018-02-06	2025-02-11	더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈	선택적인 에스트로겐 수용체 분해제로서의 치환된 벤조티오펜 유사체
AU2019321588C1 (en)	2018-08-17	2026-05-14	Genentech, Inc.	Diagnostic and therapeutic methods for the treatment of breast cancer
DK3847157T3 (da) *	2018-09-07	2022-08-08	Sanofi Sa	Fremgangsmåde til fremstilling af methyl-[6-(2,4-dichlorphenyl)-5-[4-[(3s)-1-(3-fluorpropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulen-2-carboxylat] og salt deraf
EP3699167A1 (fr)	2019-02-22	2020-08-26	Sanofi	Procédé de préparation de méthyl 1-benzosuberone-7-carboxylate
SG11202111979SA (en) *	2019-05-09	2021-11-29	Sanofi Sa	6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid for use in metastatic or advanced breast cancer patients
KR102058384B1 (ko) *	2019-09-06	2019-12-24	강원대학교산학협력단	2h-벤조[7]에눌렌 화합물 및 이의 제조방법
WO2021063967A1 (fr)	2019-10-01	2021-04-08	Sanofi	Nouveaux composés 6,7-dihydro-5h-benzo[7]annulène substitués, procédés permettant leur préparation et leurs utilisations thérapeutiques
CA3160897A1 (fr) *	2019-12-09	2021-06-17	Sanofi	Forme cristalline d'un derive d'acide 7h-benzo[7]annulene-2-carboxylique
TW202146007A (zh)	2020-02-27	2021-12-16	法商賽諾菲公司	包含阿培利司（ａｌｐｅｌｉｓｉｂ）與６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－羧酸之組合
CN113896669B (zh) *	2020-06-22	2024-12-17	海南先声再明医药股份有限公司	雌激素受体调节剂及其用途
CN115916769B (zh) *	2020-06-28	2024-09-10	深圳扬厉医药技术有限公司	并环吲唑类化合物
CN116615414A (zh) *	2020-10-19	2023-08-18	赛诺菲	经取代的6,7-二氢-5h-苯并[7]轮烯化合物及其衍生物、其制备方法及其治疗用途
IL302153B1 (en)	2020-10-19	2026-07-01	Sanofi Sa	6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS AND THEIR DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR THERAPEUTIC USES
IL302152B1 (en)	2020-10-19	2026-07-01	Sanofi Sa	6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS AND THEIR DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR THERAPEUTIC USES
EP4247977A2 (fr)	2020-11-23	2023-09-27	Sanofi	Panels de gènes régulés par er destinés à être utilisés dans la surveillance de thérapie endocrine du cancer du sein
WO2022106711A1 (fr) *	2020-11-23	2022-05-27	Sanofi	Combinaison comprenant de l'abémaciclib et de l'acide 6-(2,4-dichlorophényl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphényl]-8,9-dihydro-7h-benzo[7]annulène-2-carboxylique
US12655135B2 (en)	2021-02-04	2026-06-16	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Benzo seven-membered ring bifunctional compound and application thereof
TW202304424A (zh) *	2021-04-12	2023-02-01	法商賽諾菲公司	包含依維莫司和安森司群的組合
TW202304425A (zh) *	2021-04-12	2023-02-01	法商賽諾菲公司	包含瑞博西尼和安森司群（ａｍｃｅｎｅｓｔｒａｎｔ）的組合
TW202313558A (zh) *	2021-07-08	2023-04-01	大陸商勤浩醫藥(蘇州)有限公司	一類苯并七元環類化合物及其應用
WO2023287938A1 (fr)	2021-07-15	2023-01-19	Teva Pharmaceuticals International Gmbh	Formes à l'état solide d'amcenestrant
WO2023125700A1 (fr) *	2021-12-28	2023-07-06	南京明德新药研发有限公司	Forme saline et forme cristalline d'un composé de tétrahydrocyclohepta indazole
TW202400136A (zh)	2022-03-13	2024-01-01	法商賽諾菲公司	以安森司群(amcenestrant)治療乳癌
WO2023187086A1 (fr)	2022-03-31	2023-10-05	Sanofi	Forme solide amorphe d'amcenestrant
WO2023198905A1 (fr)	2022-04-15	2023-10-19	Sanofi	Nouveaux composés de de vinyl-n-propyl-pyrrolidine fluorés substitués, leurs procédés de préparation et leurs utilisations thérapeutiques
WO2023198879A1 (fr)	2022-04-15	2023-10-19	Sanofi	Nouveaux composés de n-propyl-pyrrolidine fluorés substitués, leurs procédés de préparation et leurs utilisations thérapeutiques
EP4508030A1 (fr)	2022-04-15	2025-02-19	Sanofi	Dérivés de 6,7-dihydro-5h-benzo[7]annulène substitués, procédés pour leur préparation et utilisations thérapeutiques associées
WO2023198901A1 (fr)	2022-04-15	2023-10-19	Sanofi	Nouveaux dérivés de 4-amino-4-oxo-but-2-ényle substitués, leurs procédés de préparation et leurs utilisations thérapeutiques
JP2025513065A (ja)	2022-04-15	2025-04-22	サノフイ	置換６，７－ジヒドロ－５ｈ－ベンゾ［７］アヌレン誘導体、それらの調製のためのプロセス及びその治療的使用
JP2025513853A (ja)	2022-04-15	2025-04-30	サノフイ	新規の置換フッ化ｎ－プロピル－ピロリジン及びｎ－プロピル－アゼチジン化合物、それらの調製のためのプロセス及びその治療的使用
WO2024006776A1 (fr) *	2022-06-27	2024-01-04	Relay Therapeutics, Inc.	Agents de dégradation des récepteurs alpha des oestrogènes et leur utilisation médicale
EP4577534A1 (fr)	2022-08-25	2025-07-02	Sanofi	Nouveaux dérivés d'acide tétrahydroisoquinoléine-6-carboxylique substitués, leurs procédés de préparation et leurs utilisations thérapeutiques
EP4577531A1 (fr)	2022-08-25	2025-07-02	Sanofi	Nouveaux dérivés d'acide 2-carbonyl-benzothiophene-6-carboxylique substitués, leurs procédés de préparation et leurs utilisations thérapeutiques
JP2025528250A (ja)	2022-08-25	2025-08-26	サノフイ	新規な置換２，３，４，９－テトラヒドロ－１ｈ－ピリド［３，４－ｂ］インドールカルボン酸誘導体、その調製方法及びその治療用途
WO2024042157A1 (fr)	2022-08-25	2024-02-29	Sanofi	Nouveaux dérivés d'acide carboxylique de quinoléine et de tétrahydronaphtalène substitués et leurs utilisations thérapeutiques
JP2025526986A (ja)	2022-08-25	2025-08-15	サノフイ	新規な置換ベンゾチオフェン－６－カルボン酸誘導体、その調製方法、及びその治療的使用
JP2025529974A (ja)	2022-09-09	2025-09-09	サノフイ	置換テトラヒドロシクロヘプタ［ｅ］インドール誘導体、それらの調製のプロセス及びその治療的使用
JP2025539034A (ja)	2022-11-11	2025-12-03	アストラゼネカ・アクチエボラーグ	癌の治療のための併用療法
CN120615091A (zh) *	2023-01-16	2025-09-09	正大天晴药业集团股份有限公司	取代的苯并七元环化合物及其应用
WO2025085738A1 (fr)	2023-10-18	2025-04-24	Halda Therapeutics Opco, Inc.	Composés hétérobifonctionnels et méthodes de traitement d'une maladie
WO2025189056A1 (fr)	2024-03-08	2025-09-12	Halda Therapeutics Opco, Inc.	Composés hétérobifonctionnels et leur utilisation dans le traitement d'une maladie

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1992015579A1 (fr) *	1991-03-08	1992-09-17	Rhone-Poulenc Rorer International (Holdings) Inc.	Composes polyaromatiques et multicycliques a base d'amines tertiaires, ayant une fonction inhibitrice de la squalenesynthetase
DE19833786A1 (de) *	1998-07-18	2000-01-20	Schering Ag	Benzocycloheptene, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
ES2236056T3 (es)	2001-01-24	2005-07-16	Chiesi Farmaceutici S.P.A.	Derivados de 2h-1-benzopirano, procedimientos para su preparacion y composiciones farmaceuticas de los mismos.
EP1417169A2 (fr) *	2001-08-11	2004-05-12	Bristol-Myers Squibb Pharma Company	Modulateurs selectifs de recepteur d'oestrogene
ATE481397T1 (de)	2002-04-24	2010-10-15	Merck Sharp & Dohme	Modulatoren des östrogenrezeptors
CA2512000C (fr)	2002-12-26	2011-08-09	Eisai Co., Ltd.	Modulateurs selectifs des recepteurs d'oestrogene
AU2004268455B2 (en) *	2003-08-29	2009-12-17	Ono Pharmaceutical Co., Ltd.	Compound capable of binding S1P receptor and pharmaceutical use thereof
ES2573845T3 (es) *	2004-06-25	2016-06-10	Janssen Pharmaceutica Nv	Antagonistas de CCR2 de sales cuaternarias
US20050288238A1 (en) *	2004-06-28	2005-12-29	Pfizer Inc	Benzocyclodecane derivatives with antitumor activity
DE102005014090A1 (de) *	2005-03-22	2006-09-28	Schering Ag	5H-Benzocycloheptenderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
CA2611712C (fr)	2005-06-14	2014-05-13	Baylor University	Analogues combrestatiniques a activite de liaison avec la tubuline
EP2048126A1 (fr) *	2007-10-11	2009-04-15	Bayer Schering Pharma AG	Dérivés de benzocycloheptanes en tant qu'oestrogènes actifs de manière sélective
EP2090579A1 (fr) *	2008-01-29	2009-08-19	Sanofi-Aventis	Dérivés d'hétéroarylamide diazépinopyrimidone substitués
DE102010030538A1 (de) *	2010-06-25	2011-12-29	Bayer Schering Pharma Aktiengesellschaft	6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
GB2483736B (en)	2010-09-16	2012-08-29	Aragon Pharmaceuticals Inc	Estrogen receptor modulators and uses thereof
US20120130129A1 (en) *	2010-11-16	2012-05-24	Baylor University	Efficient Method for Preparing Functionalized Benzosuberenes
CA2819299A1 (fr)	2010-12-24	2012-06-28	Merck Sharp & Dohme B.V.	Derives d'azetidine n-substitues
TW201329025A (zh) *	2011-11-01	2013-07-16	Astex Therapeutics Ltd	醫藥化合物
DE102011087987A1 (de)	2011-12-08	2013-06-13	Bayer Intellectual Property Gmbh	6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
CN102584687A (zh)	2011-12-30	2012-07-18	北京赛林泰医药技术有限公司	作为选择性雌激素受体调节剂的乙烯衍生物
KR20150039705A (ko) *	2011-12-30	2015-04-13	켄타우루스 바이오파마 컴퍼니 리미티드	신규 아릴알켄 유도체 및 이의 선택성 에스트로겐 수용체 조절제에 있어서의 응용
CA2901352A1 (fr) *	2013-02-19	2014-08-28	Bayer Pharma Aktiengesellschaft	2,3-benzodiazepines bicyclo- et spirocyclosubstituees
WO2015028409A1 (fr) *	2013-08-27	2015-03-05	Bayer Pharma Aktiengesellschaft	Dérivés de 6,7-dihydro-5h-benzo[7]annulène, procédé pour les préparer, préparations pharmaceutiques les contenant et leur utilisation pour fabriquer des médicaments
TWI784255B (zh)	2014-12-18	2022-11-21	瑞士商赫孚孟拉羅股份公司	四氫-吡啶并[3,4-b]吲哚雌激素受體調節劑及其用途
WO2016097071A1 (fr)	2014-12-18	2016-06-23	F. Hoffmann-La Roche Ag	Modulateurs du récepteur des œstrogènes et leurs utilisations
MX384605B (es)	2015-04-29	2025-03-14	Radius Pharmaceuticals Inc	Combinación de palbociclib y rad1901 para usarse en el tratamiento de cáncer de mama en un sujeto con cáncer positivo a receptor de estrógeno.
CN106924210A (zh)	2015-12-29	2017-07-07	北京新领先医药科技发展有限公司	一种含有帕布昔利布的胶囊剂及其制备方法
SG11201806829TA (en) *	2016-02-15	2018-09-27	Sanofi Sa	6,7-dihydro-5h-benzo[7]annulene derivatives as estrogen receptor modulators
EP3541809B1 (fr)	2016-11-17	2025-06-25	Sanofi	Composés n-(3-fluoropropyl)-pyrrolidine substitués, leurs procédés de préparation et leurs utilisations thérapeutiques

2017
- 2017-02-14 SG SG11201806829TA patent/SG11201806829TA/en unknown
- 2017-02-14 EA EA201891841A patent/EA034994B1/ru not_active IP Right Cessation
- 2017-02-14 CA CA3014424A patent/CA3014424A1/fr active Pending
- 2017-02-14 CN CN202110173352.7A patent/CN112979524B/zh active Active
- 2017-02-14 MX MX2018009908A patent/MX380091B/es unknown
- 2017-02-14 JP JP2018515615A patent/JP6425852B1/ja active Active
- 2017-02-14 WO PCT/EP2017/053282 patent/WO2017140669A1/fr not_active Ceased
- 2017-02-14 KR KR1020187026518A patent/KR102813741B1/ko active Active
- 2017-02-14 EP EP17705842.7A patent/EP3416962B1/fr active Active
- 2017-02-14 EP EP19164243.8A patent/EP3524600B1/fr active Active
- 2017-02-14 LT LTEP17705842.7T patent/LT3416962T/lt unknown
- 2017-02-14 CO CONC2018/0009534A patent/CO2018009534A2/es unknown
- 2017-02-14 BR BR112018016490-9A patent/BR112018016490A2/pt active Search and Examination
- 2017-02-14 MY MYPI2022006892A patent/MY206566A/en unknown
- 2017-02-14 TW TW110118421A patent/TWI779621B/zh not_active IP Right Cessation
- 2017-02-14 SI SI201730819T patent/SI3416962T1/sl unknown
- 2017-02-14 DK DK19164243.8T patent/DK3524600T3/da active
- 2017-02-14 TW TW110118420A patent/TWI779620B/zh not_active IP Right Cessation
- 2017-02-14 PT PT177058427T patent/PT3416962T/pt unknown
- 2017-02-14 HU HUE19164243A patent/HUE057892T2/hu unknown
- 2017-02-14 AU AU2017221083A patent/AU2017221083B2/en not_active Ceased
- 2017-02-14 MX MX2020011469A patent/MX386677B/es unknown
- 2017-02-14 KR KR1020227002702A patent/KR102813742B1/ko active Active
- 2017-02-14 EA EA202090255A patent/EA038639B1/ru unknown
- 2017-02-14 CR CR20180442A patent/CR20180442A/es unknown
- 2017-02-14 MA MA44226A patent/MA44226B1/fr unknown
- 2017-02-14 ES ES17705842T patent/ES2881508T3/es active Active
- 2017-02-14 CN CN201780023088.0A patent/CN108884079B/zh active Active
- 2017-02-14 UY UY0001037124A patent/UY37124A/es not_active Application Discontinuation
- 2017-02-14 MA MA046479A patent/MA46479A/fr unknown
- 2017-02-14 PE PE2018001528A patent/PE20181893A1/es unknown
- 2017-02-14 RS RS20210923A patent/RS62132B1/sr unknown
- 2017-02-14 TN TNP/2018/000285A patent/TN2018000285A1/en unknown
- 2017-02-14 SG SG10202106024XA patent/SG10202106024XA/en unknown
- 2017-02-14 MY MYPI2018702684A patent/MY196486A/en unknown
- 2017-02-14 ES ES19164243T patent/ES2906208T3/es active Active
- 2017-02-14 PL PL17705842T patent/PL3416962T3/pl unknown
- 2017-02-14 HR HRP20211043TT patent/HRP20211043T1/hr unknown
- 2017-02-14 AR ARP170100360A patent/AR107616A1/es unknown
- 2017-02-14 HU HUE17705842A patent/HUE055107T2/hu unknown
- 2017-02-14 TW TW106104698A patent/TWI737681B/zh not_active IP Right Cessation
- 2017-02-14 US US15/432,470 patent/US9714221B1/en active Active
- 2017-02-14 DK DK17705842.7T patent/DK3416962T3/da active
- 2017-06-05 US US15/613,689 patent/US10570090B2/en active Active
2018
- 2018-07-31 ZA ZA2018/05137A patent/ZA201805137B/en unknown
- 2018-08-07 PH PH12018501679A patent/PH12018501679A1/en unknown
- 2018-08-10 DO DO2018000184A patent/DOP2018000184A/es unknown
- 2018-08-10 CL CL2018002290A patent/CL2018002290A1/es unknown
- 2018-08-12 IL IL261099A patent/IL261099B/en active IP Right Grant
- 2018-09-13 EC ECSENADI201869466A patent/ECSP18069466A/es unknown
- 2018-10-22 JP JP2018198269A patent/JP6476343B2/ja active Active
2019
- 2019-02-01 JP JP2019016703A patent/JP6695457B2/ja active Active
2020
- 2020-01-15 US US16/743,504 patent/US20200392081A1/en not_active Abandoned
- 2020-04-21 JP JP2020075207A patent/JP6868142B2/ja active Active
- 2020-10-01 IL IL277750A patent/IL277750B/en unknown
- 2020-12-17 US US17/124,852 patent/US11214541B2/en active Active
2021
- 2021-09-02 AU AU2021225215A patent/AU2021225215B2/en not_active Expired - Fee Related
- 2021-11-22 US US17/532,051 patent/US20220073460A1/en not_active Abandoned
2022
- 2022-02-16 CY CY20221100140T patent/CY1125165T1/el unknown
2023
- 2023-10-12 US US18/379,576 patent/US20240150284A1/en not_active Abandoned
2025
- 2025-03-06 US US19/072,120 patent/US20250368605A1/en active Pending

Also Published As

Publication number	Publication date
EP3524600B1 (fr)	2021-11-17
US20170233340A1 (en)	2017-08-17
CO2018009534A2 (es)	2018-09-20
MY196486A (en)	2023-04-17
MX380091B (es)	2025-03-11
CR20180442A (es)	2018-12-21
TWI779621B (zh)	2022-10-01
MX2018009908A (es)	2018-09-07
DOP2018000184A (es)	2019-01-31
AU2021225215A1 (en)	2021-09-30
ZA201805137B (en)	2023-09-27
DK3524600T3 (da)	2022-02-07
MX2020011469A (es)	2021-09-30
IL261099B (en)	2020-10-29
TWI779620B (zh)	2022-10-01
JP6425852B1 (ja)	2018-11-21
TN2018000285A1 (en)	2020-01-16
UY37124A (es)	2017-09-29
CA3014424A1 (fr)	2017-08-24
JP2019031537A (ja)	2019-02-28
AU2017221083A1 (en)	2018-10-04
IL261099A (en)	2018-10-31
JP2019081776A (ja)	2019-05-30
US20250368605A1 (en)	2025-12-04
LT3416962T (lt)	2021-07-12
EP3416962A1 (fr)	2018-12-26
PT3416962T (pt)	2021-07-23
JP6476343B2 (ja)	2019-02-27
JP2018537406A (ja)	2018-12-20
AU2021225215B2 (en)	2023-05-25
US20180079720A1 (en)	2018-03-22
US9714221B1 (en)	2017-07-25
US20240150284A1 (en)	2024-05-09
EA202090255A3 (ru)	2020-07-31
US20200392081A1 (en)	2020-12-17
PE20181893A1 (es)	2018-12-11
TW202138349A (zh)	2021-10-16
EP3524600A1 (fr)	2019-08-14
MX386677B (es)	2025-03-19
CL2018002290A1 (es)	2018-10-05
RS62132B1 (sr)	2021-08-31
CN112979524B (zh)	2024-09-10
US10570090B2 (en)	2020-02-25
PL3416962T3 (pl)	2021-11-22
MA44226B1 (fr)	2021-07-29
HRP20211043T1 (hr)	2021-10-01
SG10202106024XA (en)	2021-07-29
CY1125165T1 (el)	2023-06-09
TW202138348A (zh)	2021-10-16
CN108884079A (zh)	2018-11-23
DK3416962T3 (da)	2021-07-26
US20220073460A1 (en)	2022-03-10
EA202090255A2 (ru)	2020-05-31
IL277750A (en)	2020-11-30
ECSP18069466A (es)	2018-09-30
ES2906208T3 (es)	2022-04-13
US20210323916A1 (en)	2021-10-21
KR20180105759A (ko)	2018-09-28
TW201741285A (zh)	2017-12-01
KR102813741B1 (ko)	2025-05-28
SG11201806829TA (en)	2018-09-27
AR107616A1 (es)	2018-05-16
JP6868142B2 (ja)	2021-05-12
WO2017140669A1 (fr)	2017-08-24
KR20220098057A (ko)	2022-07-08
HUE057892T2 (hu)	2022-06-28
JP2020128385A (ja)	2020-08-27
BR112018016490A2 (pt)	2018-12-18
EP3416962B1 (fr)	2021-05-05
IL277750B (en)	2022-06-01
EA038639B1 (ru)	2021-09-28
KR102813742B1 (ko)	2025-05-28
SI3416962T1 (sl)	2021-08-31
EA201891841A1 (ru)	2019-01-31
CN112979524A (zh)	2021-06-18
EA034994B1 (ru)	2020-04-15
ES2881508T3 (es)	2021-11-29
MY206566A (en)	2024-12-21
PH12018501679A1 (en)	2019-06-10
CN108884079B (zh)	2021-03-05
AU2017221083B2 (en)	2021-06-24
US11214541B2 (en)	2022-01-04
JP6695457B2 (ja)	2020-05-20
TWI737681B (zh)	2021-09-01
HUE055107T2 (hu)	2021-10-28

Publication	Publication Date	Title
EP3315512A4 (fr)	2019-02-13	Procédé pour la préparation sélective d'un conjugué anticorps-médicament
EP3353841A4 (fr)	2019-06-05	Procédé de préparation et d'application de composites de carbone-sélénium
EP3707260A4 (fr)	2021-08-04	Composés et procédés permettant de réduire l'expression de snca
EP3463665A4 (fr)	2020-03-25	Surfaces modifiées par covalence, kits et procédés de préparation et d'utilisation
MA44127A (fr)	2018-10-31	Procédés de synthèse pour la préparation de di(4-méthylbenzènesulfonate) de 2-amino-3-méthylbutanoate de (s)-(2r,3r,11br)-3-isobutyl-9,10-diméthoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1,-a]isoquinoléin-2-yl
DK3524600T3 (da)	2022-02-07	Fremgangsmåder og mellemprodukter til fremstilling af hidtil ukendte substituerede 6,7-dihydro-5h-benzo[7]annulenforbindelser
EP3353278A4 (fr)	2019-03-06	Préparation d'échantillons pour des types d'échantillons compliqués
MA50045A (fr)	2020-07-08	Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci
EP3519572A4 (fr)	2020-06-17	Composés et procédés pour réduire l'expression de tau
MA46791A (fr)	2019-09-18	Composés et procédés pour réduire l'expression d'atxn3
EP3504196A4 (fr)	2020-01-22	Procédés de préparation d'olaparib
EP3706725A4 (fr)	2021-08-25	Processus pour la préparation de tapinarof
EP3695433A4 (fr)	2021-07-07	Procédé de préparation d'échantillon de section transversale
MA52906A (fr)	2021-04-21	Procédé de préparation d'amg 416
EP3495362A4 (fr)	2019-12-18	Dérivé de l'acide thioglycolique imidazopyridine, son procédé de préparation et son application
MA50041A (fr)	2020-07-08	Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci
EP3645529A4 (fr)	2021-03-10	Procédé pour la préparation de lifitegrast et d'intermédiaires de celui-ci
EP3728241A4 (fr)	2021-02-24	Procédé de préparation d'opicapone et d'intermédiaires de celui-ci
ES2837136R1 (es)	2023-08-18	Proceso para la preparación de 3alfa-hidroxi-5alfa-pregnan-20-ona (Brexanolona)
EP3648773A4 (fr)	2021-06-09	Composés et procédés pour l'administration transmembranaire de molécules
EP3372596A4 (fr)	2019-05-08	Procédé de préparation de tédizolide, intermédiaire de tédizolide et procédé pour sa préparation
MA46641A (fr)	2019-09-04	Méthodes et compositions permettant d'empêcher la transmission de maladies propagées par un vecteur
MA53370A (fr)	2021-06-02	Procédé et intermédiaires pour la préparation de bilastine
MA46431A (fr)	2019-08-07	Composés et procédés pour réduire l'expression de tau
EP3431520A4 (fr)	2019-11-27	Procédé de préparation d'un copolymère d'oxyméthylène